Loading
NASDAQTechnologySoftware - Application
Latest quote
$18.50
$0.00 · 0.00%
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
Previous close
$18.50
$0.00 · 0.00%
Regular session · ET · Market data may be delayed.
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
52-week range
Current $18.50
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
73
Undervalued
Sentiment
64
Bullish
Risk
49
Elevated Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
52-week range
Current $18.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 79.18M USD | 70.01M USD | 59.58M USD | 53.91M USD | 46.47M USD |
| Cost of goods sold | 32.96M USD | 26.86M USD | 11.63M USD | 10.82M USD | 10.6M USD |
| Gross profit | 46.22M USD | 43.15M USD | 47.95M USD | 43.08M USD | 35.87M USD |
| Research and development | 6.88M USD | 5.75M USD | 4.5M USD | 3.21M USD | 4.05M USD |
| Selling, general, and administrative | 32.85M USD | 31.27M USD | 34.72M USD | 24.97M USD | 20.57M USD |
| Operating expenses | 116.95M USD | 37.02M USD | 39.22M USD | 28.17M USD | 24.61M USD |
| Interest income | 722K USD | 4.38M USD | 4.13M USD | 717K USD | 201K USD |
| Interest expense | — | — | — | — | 22K USD |
| Depreciation and amortization | 8.21M USD | 5.67M USD | 3.84M USD | 3.57M USD | 3.59M USD |
| Operating income | −70.73M USD | 6.13M USD | 8.73M USD | 14.91M USD | 11.25M USD |
| Net income | −64.72M USD | 9.95M USD | 9.96M USD | 12.48M USD | 9.78M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$18.50
0.00% upsidePrice history unavailable
High $18.50Average $18.50Low $18.50Cash distributions grouped by calendar year; partial years are marked.
$0.24
2023 complete year0.0% since 2019
$0.24
2,019
$0.24
2,020
$0.24
2,021
$0.24
2,022
$0.24
2,023
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 29, 2024 | $0.06Quarterly | Jul 29, 2024 | Aug 5, 2024 |
Dividend | Apr 26, 2024 | $0.06Quarterly | Apr 29, 2024 | May 6, 2024 |
Dividend | Jan 26, 2024 | $0.06Quarterly | Jan 29, 2024 | Feb 5, 2024 |
Dividend | Oct 27, 2023 | $0.06Quarterly | Oct 30, 2023 | Nov 6, 2023 |
Dividend | Jul 28, 2023 | $0.06Quarterly | Jul 31, 2023 | Aug 7, 2023 |
Dividend | Apr 21, 2023 | $0.06Quarterly | Apr 24, 2023 | May 1, 2023 |
Ex-dividend Jul 29, 2024
$0.06
Quarterly
Record Jul 29, 2024 · Payment Aug 5, 2024
Ex-dividend Apr 26, 2024
$0.06
Quarterly
Record Apr 29, 2024 · Payment May 6, 2024
Ex-dividend Jan 26, 2024
$0.06
Quarterly
Record Jan 29, 2024 · Payment Feb 5, 2024
Ex-dividend Oct 27, 2023
$0.06
Quarterly
Record Oct 30, 2023 · Payment Nov 6, 2023
Ex-dividend Jul 28, 2023
$0.06
Quarterly
Record Jul 31, 2023 · Payment Aug 7, 2023
Ex-dividend Apr 21, 2023
$0.06
Quarterly
Record Apr 24, 2023 · Payment May 1, 2023
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI9.89M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF3.62M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO1.81M0.01%18B USD0.06%$112.1-0.10%
Vanguard Health Care ETFVHT968.83K0.00%22B USD0.09%$313.85-0.46%
JPMorgan Diversified Return U.S. Small Cap Equity ETFJPSE473.16K0.08%571.22M USD0.29%$57.179+0.61%
Vanguard Russell 2000 Growth ETFVTWG238.76K0.01%1.7B USD0.06%$258.14-0.44%
WisdomTree U.S. SmallCap FundEES197.08K0.03%683.92M USD0.38%$65.45+0.60%
Vanguard Russell 2000 Value ETFVTWV87.36K0.01%1.4B USD0.06%$186.06+0.59%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTJPMorgan Diversified Return U.S. Small Cap Equity ETFJPSEVanguard Russell 2000 Growth ETFVTWGWisdomTree U.S. SmallCap FundEESVanguard Russell 2000 Value ETFVTWVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
